Τόμος 1 (1983) – Τεύχος 4 – Άρθρο 4 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 1 (1983) – Issue 4 – Article 4 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Action des Médicaments sur la Fonction Plaquettaire chez les Diabétiques avec Microangiopathie

Courten de, A.: Action des Médicaments sur la Fonction Plaquettaire chez les Diabétiques avec Microangiopathie, Epitheorese Klin. Farmakol. Farmakokinet. 1(4): 270-279 (1983)

Diabète, Microangiopathie, traitement des thromboses

2.         Laurintzen, T. et al.: Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. The Lancet, Jan. 29: 200 (1983)

3.         Knzywanck, H.H., Breddin, K.: Platelet aggregation as a risk factor in diabetic subjects. Pathogenetic concepts of diabetic microangioplasty. International Workshop Garmisch — Grainau, 1980, p. 11. Edited by Georg Thieme Verlag, 1981

4.         Régnault, F., Duhault, J., Schaub, C.: Les modifications générales à Γ origine de la rétinopathie diabétique. Gaz. Méd. France No 13: 85 (1978)

5.         Stoltz, J.F., Voisin, Ph„ Genisti, G.: Dosage du malonaldéhyde plaquettaire chez les diabétiques. La Nouvelle Presse Médicale No 4: 250 (1980)

6.         Bouvier, C.A.: Plaquettes et thromboses. Acta Clin. Belg. 30: 3 (1975)

7.         Monkada, S., Vane, J.R.: Biological significance and therapeutic potential of prostacyclin. J. Med. Chem. 23: 591 (1980)

8.         Mannucci, P.M., Pereti, F.I.: Platelet functions after i.v. administration in man of cyclic AMP and related drugs. J. Lab. Clin. Med. 84: 828 (1974)

9.         Gellus, A.S.: Antiplatelet drugs, clinical pharmacology and therapeutic use. Med. Prog. Jan. 1980

10.       Weiss, H.J.: Platelet physiology and abnormalities of platelet functin. The New England Journal of Medicine, Vol. 293, No. 12. Sept. 18, 1975

11.        Gringauz, A.: Drugs: how they act and why. The C.V. Mosby Co., Saint Louis, 1978

12.       Editorial: Circulating prostacyclin. Lancet 2: 21 (1978)

13.       Dollery, C.T., Hensby, C.N.: Is prostacyclin a circulating anti-coagulant. Nature 273: 706 (1978)

14.       Weiss, H.J.: Antiplatelet therapy. N. Engl. J. Med. 298: 1344, 1403 (1978)

15.       Ylikorkala, O., Kaila, J., Vinikka, L: Prostacyclin and thromboxane in diabetes. Br. Med. J. 283: 1148 (1981)

16.       Laurence, D.R., Bennett, P.N.: Clinical Pharmacology. 5^th edition, p. 426, (1980)

17.       Burch, J.W., Stanford, N., Majerus, P.W.: Inhibition of platelet prostaglandin synthetase by oral aspirin, J. Clin. Invest. 61: 314 (1978)

18.       Roth, G.J., Sick, C.J.: Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin. J. Biol. Chem. 253: 3782 (1978)

19.       Jobin, F.: Acetylsalicylic acid, haemostasis and human thromboembolism. Seminars in Thrombosis and Hemostasis 4:199 (1978)

20.      Moncada, S.r Vane, J.R.: Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br. Med. Bull. 34: 129 (1978)

21.       O’ Grady, J., Moncada, S.: Aspirin: A paradoxical effect on bleeding-time. Lancet 2: 780 (1978)

22.       Monkada, S., Korbutt, R.: Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet I: 1286 (1978)

23.       Ritchie, J.L., Harker, L.A.: Platelet and fibrinogen survival in coronary atherosclerosis. Response to medical and surgical therapy. Am. J. Card. 39: 595 (1977)

24.       Steele, P., Rainwater, J., Vogel, R., Genton, E.: Platelet-suppressant therapy in patients with coronary artery disease. J. Am, Med. Ass. 240: 228 (1978)

25.       DeGaetano et al.: L’ inhibition de l’ agrégation plaquettaire, données expérimentales et perspectives cliniques. Nouv. Rev. Franç. Hématol. U: 339 (1971)

26.       Goodman, L.S., Gilman, A, (eds): The Pharmacological Basis of Therapeutics. 6th E., MacMilan Pub. Co., New York, 1980

27.       Ali, M., McDonald, J.W.D.: Effects of sulfinpyrazone on platelet prostaglandin synthesis and platelet release of serotonin. J. Lab. Clin. Med. 89: 868 (1977)

28.      Steele, P.P., Weily, H.S., Genton, E.: Platelet survival and adhesiveness in recurrent venous thrombosis, N. Engl. J. Med. 288: 1148 (1973)

29.       Steele, P.P., Ellis, J., Genton, E.: Effects of platelet suppressant, anticoagulant and fibrinolytic therapy in patients with recurrent venous thrombosis. Am. J. Med. 64: 441 (1978)

30.      Kaegi, A., Pinéo, G.F., Shimizu, A„ Trivedi, H., Hirsh, J., Gent, M.: The role of sulfinpyrazone in the prevention of arteriovenous shunt thrombosis. Circulation 52: 497 (1975)

31.       Benakis, A., Glasson, B., Bouvier, C.A., Ritschard, J., Krahenbuhl, B., Jung, A., Hachen, H.J.: Métabolisme et pharmacocinétique du dobësilate de calcium chez ) homme. Thérapie 29: 211 (1974)

32.       Plessas, Ch.T., Plessas, S.T., Benakis, A.; Pharmacokinetics of. calcium dobesilate in man after rapid intravenous administration. XII World Congress of Angiology, Book of abstracts, p. 365, Athens 1980

33.       Plessas, Ch.T., Varonos, D., Plessas, S.T., Cokkinos, D., Voridis, E.: Calcium 35S-Dobesilate blood studies in the rabbit. Acta Ther. 5: 341 (1979)

34.       Beyer, J., Meissner, K.O., Happ, J., Cordes, U.: Die Wirkung von Calcium-debesilt auf die Permeation von Plasmaproteinen beim Dibetiker. Deutsche Medizinische Wochenschrift 46: 1604 (1980)

35.       Kappert, A.: Zur medikamentösen Beeinflussung gestörter Kapillarfunktionen. Zeitschrift für Therapie 12: 71 (1974)

36.       Sevin-, R., Cuendet, J.F.: The action of calcium dobesilate on capillary permeability in diabetics. Opithalmofogica 163: 33 (1971)

37.. Thomas, J., Dorme, N., Sergant, M., Raynaud, G., Bouvet, P.: Action du dobesilate de calcium sur ta résistance et la perméabilité capillaires et sur le temps de saignement et l ‘ adhésivité plaquettaire modifiés par le Dextran Annal Pharmac. Franç. 30, 6: 415 (1972)

38.      Heidrich, H., Hoefner, -J., Schneider, D., Wollensak, J.: Thrombozytenaggregation unter Kalziumdobesilat. (Dexium), Klinische Studie in Mikrozirkulation und Blutrheologie I, 259-260. Therapie der peripheren arteriellen Verschluss-krankheit, edited by H. Müller-Wiefel, Gerhard Witzstrock, Baden-Baden, W. Germany, 1980

39.       Michal, M., Crotti, C., Giessinger, N.: Effect of Doxium on platelet function in vivo and in vitro. XVIIIth Congress of Eur. Soc. Surg. Res. Athens, 1983

40.      Sack, E.S.; In vitro effect of Doxium on platelet functions. VI Congrès Mondial de Phlébologie, Buenos Aires, 1977

41.       Falkay, G., Kovacs, L: Calcium dobesilate (Doxium) as a prostaglandin synthetase inhibitor in pregnant human myometrium in vitro. Experientia (in press)

42.       Barras, J.P., Graf, C.: Hyperviscosity in diabetic retinopathy treated with Doxium (calcium dobesilate). Vasa 9: 161 (1980)

43.       Hudomel, J., Nemeth, B., Palfalvy, M., Farkas, A.: Effect of calcium dobesilate (Doxium) on blood hyperviscosity in cases of diabetic retinopathy. Ophthalmic Res. 9: 25 (1977)

44.       Plessas, S.T., Plessas, Ch.T., Benakis, A.: Correlations entre modifications rhéologiques au niveau sanguin et liaison avec les constituants du sand du Doxium. XII World Congress of Angiology, Book of abstracts, p. 284, Athens 1980